Theriva Biologics, Inc. (TOVX)
0.144
0.00 (0.00%)
USD |
NYAM |
Nov 18, 16:00
0.1421
0.00 (0.00%)
After-Hours: 20:00
Theriva Biologics Enterprise Value : 1.562M for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 1.562M |
| November 17, 2026 | 1.379M |
| November 16, 2026 | 1.379M |
| November 13, 2026 | 1.567M |
| November 12, 2026 | 2.297M |
| November 11, 2026 | 2.338M |
| November 10, 2026 | 2.031M |
| November 09, 2026 | 2.563M |
| November 06, 2026 | 2.595M |
| November 05, 2026 | 2.682M |
| November 04, 2026 | 3.674M |
| November 03, 2026 | 3.306M |
| November 02, 2026 | 3.398M |
| October 30, 2026 | 2.779M |
| October 29, 2026 | 3.536M |
| October 28, 2026 | 3.669M |
| October 27, 2026 | 3.582M |
| October 26, 2026 | 3.830M |
| October 23, 2026 | 3.949M |
| October 22, 2026 | 3.674M |
| October 21, 2026 | 3.976M |
| October 20, 2026 | 4.500M |
| October 19, 2026 | 4.348M |
| October 16, 2026 | 4.495M |
| October 15, 2026 | 4.683M |
| Date | Value |
|---|---|
| October 14, 2026 | 4.587M |
| October 13, 2026 | 4.853M |
| October 12, 2026 | 5.023M |
| October 09, 2026 | 4.913M |
| October 08, 2026 | 5.376M |
| October 07, 2026 | 5.693M |
| October 06, 2026 | 5.142M |
| October 05, 2026 | 5.280M |
| October 02, 2026 | 5.284M |
| October 01, 2026 | 5.280M |
| September 30, 2026 | 5.280M |
| September 29, 2026 | 1.854M |
| September 28, 2026 | 2.152M |
| September 25, 2026 | 2.340M |
| September 24, 2026 | 2.794M |
| September 23, 2026 | 2.987M |
| September 22, 2026 | 2.808M |
| September 21, 2026 | 2.808M |
| September 18, 2026 | 2.932M |
| September 17, 2026 | 3.322M |
| September 16, 2026 | 2.588M |
| September 15, 2026 | 2.546M |
| September 14, 2026 | 3.028M |
| September 11, 2026 | 3.579M |
| September 10, 2026 | 3.354M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.176B |
| Alnylam Pharmaceuticals, Inc. | 19.41B |
| Anika Therapeutics, Inc. | 163.62M |
| Savara, Inc. | 870.84M |
| Arrowhead Pharmaceuticals, Inc. | 6.299B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.471M |
| Total Expenses (Quarterly) | 1.471M |
| EPS Diluted (Quarterly) | -0.032 |
| Earnings Yield | -173.7% |
| Normalized Earnings Yield | -183.96 |